Ken Miller
CEO

Spectrum Vascular develops and provides advanced vascular access devices designed to improve medication delivery and patient outcomes. Their products focus on enhancing the safety and efficacy of intravenous therapies while reducing complications associated with vascular access.
CEO
Vascular access complications, such as catheter-related bloodstream infections (CRBSIs) and thrombus accumulation, pose significant risks to patients requiring intravenous therapies. These complications can lead to increased healthcare costs, longer hospital stays, and reduced patient satisfaction.
Spectrum Vascular provides a portfolio of vascular access devices designed to mitigate common and costly complications. Their SV Spectrum™ catheters utilize minocycline and rifampin impregnation to provide antimicrobial protection against CLABSIs and CRBSIs. The SV BioFlo catheters incorporate Endexo® technology, a surface-modifying macromolecule, to reduce thrombus accumulation and related catheter complications. By offering solutions focused on infection prevention and thrombus reduction, Spectrum Vascular aims to improve patient outcomes and reduce the economic burden associated with vascular access procedures.
Spectrum Vascular's products are intended for use by healthcare providers, including physicians, nurses, and other clinicians, in hospitals, clinics, and other healthcare settings.